Pacira BioSciences (PCRX) Operating Margin (2010 - 2026)
Pacira BioSciences (PCRX) posted Operating Margin of 2.22% for Q2 2026, down 43.0% on a QoQ basis from 3.89% in Q1 2026, and down 248.0% year-over-year from 1.5% in Q2 2025.
Powered by 
Analysis
Pacira BioSciences (PCRX) Operating Margin (2010 - 2026) Analysis & Trends
Pacira BioSciences has reported Operating Margin for 17 years, with the latest figure at 2.22% in Q2 2026.
- On a quarterly basis, Operating Margin fell 248.0% year-over-year to 2.22% in Q2 2026; TTM through Jun 2026 was 2.66%, a 1744.0% increase from a year earlier, with the FY2025 full-year figure at 2.64%, up 1311.0% from the prior year.
- Operating Margin was 2.22% for Q2 2026 at Pacira BioSciences, down from 3.89% in the prior quarter.
- The five-year high for Operating Margin was 23.53% in Q2 2023, with the low at 82.77% in Q3 2024.
- Average Operating Margin over 5 years is 3.22%, with a median of 6.3% recorded in 2024.
- The sharpest annual moves came in 2024 and 2025: Operating Margin slumped 9358 bps in 2024, then soared 8631 bps in 2025.
- Over 5 years, Operating Margin stood at 5.75% in 2022, then jumped by 418 bps to 18.3% in 2023, then dropped by 28 bps to 13.19% in 2024, then tumbled by 91 bps to 1.19% in 2025, then soared by 87 bps to 2.22% in 2026.
- The last three Operating Margin figures came in at 2.22% (Q2 2026), 3.89% (Q1 2026), and 1.19% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.46 Bn | 622.70 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 440.39 Bn | 433.82 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 364.93 Bn | 357.79 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 266.64 Bn | 258.95 Bn | 11.24 Bn | 32.97% |
| 5 | Pfizer | 158.92 Bn | 147.22 Bn | 10.94 Bn | 28.37% |
| 6 | Sanofi | 52.46 Bn | 45.08 Bn | 10.79 Bn | 9.03% |
| 7 | Revolution Medicines | 44.36 Bn | 44.36 Bn | - | - |
| 8 | Incyte | 25.34 Bn | 20.81 Bn | 1.57 Bn | 41.69% |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn | 42.23% |
| 10 | Pacira BioSciences | 1.01 Bn | 756.04 Mn | 148.24 Mn | 2.22% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.22% |
| Mar 31, 2026 | 3.89% |
| Dec 31, 2025 | 1.19% |
| Sep 30, 2025 | 3.54% |
| Jun 30, 2025 | 4.69% |
| Mar 31, 2025 | 1.18% |
| Dec 31, 2024 | 13.19% |
| Sep 30, 2024 | -82.77% |
| Jun 30, 2024 | 15.86% |
| Mar 31, 2024 | 7.91% |
| Dec 31, 2023 | 18.30% |
| Sep 30, 2023 | 10.81% |
| Jun 30, 2023 | 23.53% |
| Mar 31, 2023 | -1.93% |
| Dec 31, 2022 | -5.75% |
| Sep 30, 2022 | 12.71% |
| Jun 30, 2022 | 18.44% |
| Mar 31, 2022 | 11.01% |
| Dec 31, 2021 | 2.65% |
| Sep 30, 2021 | 24.61% |